E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


Pregnancy with epilepsy and antiepileptic drug therapy on fetomaternal outcome

Jyothinath Kothapalli.

Abstract
Background: Pregnancy women with epilepsy may have higher chances of obstetric complications, aggregative seizures, major congenital malformations, and abnormal deliveries. Monotherapy or polytherapy of anti-epileptic drugs are usually associated with adverse outcomes in pregnant women with epilepsy.

Aim and Objectives: The aim of the study was to evaluate the effect of epilepsy and antiepileptic drug (AED) therapy on the fetomaternal outcome in pregnant women.

Material and Methods: A total of 46 pregnant women with epileptic seizures between 18 and 35 years with mean age of 26.46 years were included in the study. The demographic, clinical, and obstetrical data were collected from the medical records. The AED monotherapy and polytherapy with drug dosage details were noted. The details of mode of delivery, outcome of seizures in post-natal period and fetal outcome were gathered.

Results: About 65.21% cases were under AED polytherapy and 34.78% cases were under AED monotherapy. Majority cases had carbamazepine (CBZ) and sodium valproate mono and polytherapy. Majority had normal vaginal delivery (65.11%). Single or in combination use of sodium valproate, CBZ, and phenytoin are associated with major congenital malformations (9%). Postpartum hemorrhage was observed in 6.52% cases and postpartum seizure occurrence was observed in 8.69% cases.

Conclusion: A well planned pregnancy, continuous monitoring for congenital malformations and fetal growth restriction is necessary in pregnant women under AED therapy for better maternal and fetal outcome.

Key words: Pregnancy; Anti-epileptic Drugs; Major Congenital Malformations


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Jyothinath Kothapalli
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Jyothinath Kothapalli. Pregnancy with epilepsy and antiepileptic drug therapy on fetomaternal outcome. Natl J Physiol Pharm Pharmacol. 2022; 12(5): 624-628. doi:10.5455/njppp.2022.12.10390202101112021


Web Style

Jyothinath Kothapalli. Pregnancy with epilepsy and antiepileptic drug therapy on fetomaternal outcome. https://www.njppp.com/?mno=136214 [Access: May 02, 2022]. doi:10.5455/njppp.2022.12.10390202101112021


AMA (American Medical Association) Style

Jyothinath Kothapalli. Pregnancy with epilepsy and antiepileptic drug therapy on fetomaternal outcome. Natl J Physiol Pharm Pharmacol. 2022; 12(5): 624-628. doi:10.5455/njppp.2022.12.10390202101112021



Vancouver/ICMJE Style

Jyothinath Kothapalli. Pregnancy with epilepsy and antiepileptic drug therapy on fetomaternal outcome. Natl J Physiol Pharm Pharmacol. (2022), [cited May 02, 2022]; 12(5): 624-628. doi:10.5455/njppp.2022.12.10390202101112021



Harvard Style

Jyothinath Kothapalli (2022) Pregnancy with epilepsy and antiepileptic drug therapy on fetomaternal outcome. Natl J Physiol Pharm Pharmacol, 12 (5), 624-628. doi:10.5455/njppp.2022.12.10390202101112021



Turabian Style

Jyothinath Kothapalli. 2022. Pregnancy with epilepsy and antiepileptic drug therapy on fetomaternal outcome. National Journal of Physiology, Pharmacy and Pharmacology, 12 (5), 624-628. doi:10.5455/njppp.2022.12.10390202101112021



Chicago Style

Jyothinath Kothapalli. "Pregnancy with epilepsy and antiepileptic drug therapy on fetomaternal outcome." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 624-628. doi:10.5455/njppp.2022.12.10390202101112021



MLA (The Modern Language Association) Style

Jyothinath Kothapalli. "Pregnancy with epilepsy and antiepileptic drug therapy on fetomaternal outcome." National Journal of Physiology, Pharmacy and Pharmacology 12.5 (2022), 624-628. Print. doi:10.5455/njppp.2022.12.10390202101112021



APA (American Psychological Association) Style

Jyothinath Kothapalli (2022) Pregnancy with epilepsy and antiepileptic drug therapy on fetomaternal outcome. National Journal of Physiology, Pharmacy and Pharmacology, 12 (5), 624-628. doi:10.5455/njppp.2022.12.10390202101112021